Reference
Golijanin B, et al. PEMBROLIZUMAB FOR BCG REFRACTORY NON-MUSCLE INVASIVE BLADDER CANCER YIELDS POOR RECURRENCE-FREE SURVIVAL AND HIGH TOXICITY IN PATIENTS. Journal for ImmunoTherapy of Cancer 11 (Suppl. 1): A492 abstr. 443, Nov 2023. Available from: URL: https://dx.doi.org/10.1136/jitc-2023-SITC2023.0443 [abstract]
Rights and permissions
About this article
Cite this article
BCG. Reactions Weekly 1992, 48 (2024). https://doi.org/10.1007/s40278-024-52781-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-024-52781-y